Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Myvac

Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

ASCO 2025 TG4050 webinar

Published 3 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccin TG4050

ASCO TG4050

Published 1 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

ASCO 2025 TG4050

Published 1 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

ASCO Abstract

Published 22 May 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

ASCO 2025 TG4050

Published 22 May 2025
Categorized as 2025, Myvac, Press release, TG4050

Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)

C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Rapid Oral Presentation

Published 22 May 2025
Categorized as 2025, Myvac, Publication, publication key en, TG4050

Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

ASCO 2025 curtain

Published 23 April 2025
Categorized as 2025, Myvac, Press release, TG4050

Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)

C. Le Tourneau, et al. SITC 2024  Abstract available on the SITC website – Download the abstract and the poster

Published 7 November 2024
Categorized as 2024, Myvac, Publication, publication key en, TG4050

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

SITC 2024

Published 7 November 2024
Categorized as 2024, Myvac, Press release, TG4050

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment

ProBioGen

Published 5 November 2024
Categorized as 2024, categorie-orpheline, dates, dates, Myvac, Press release

Posts pagination

Newer posts Page 1 … Page 3 … Page 7 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu